This article was originally published in The Gray Sheet
Firm agrees to buy a majority interest in OST Developpement SA from parent Transphyto SA in a two-step transaction valued at $1.5 mil. The deal entails the June 25 purchase of 5% interest in the company; an additional 85% stake will be acquired no later than March 1999, provided OST achieves certain milestones, Osteotech says. The agreement allows for the purchase of the remaining 10% of OST at an undetermined price. Purchase of the French bovine bone graft manufacturer is expected to add $4 mil. to Osteotech's top-line and be accretive to earnings in 1999
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.